Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
Date:11/8/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2012 financial results and highlighted key clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced completion of patient enrollment in the primary registration Phase 3 SYNERGY study. The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). Over 1000 men have now been enrolled.  The survival primary endpoint data are event-driven and results are expected by the end of 2013.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in approximately 630 men with CRPC, was initiated in the third quarter. This global study will be conducted at sites throughout North America, Europe and Australia.
  • The ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC), was initiated in the third quarter. The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line chemotherapy in patients who have progressed after initial chemotherapy treatment has failed.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the European Society for Medical Oncology Annual Meeting (ESMO) in September 2012. The updated study results showed a higher number of patients without disease progression at 12 weeks and grea
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    4. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    5. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    6. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    7. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    9. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
    11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Dallas, Texas (PRWEB) August 21, 2014 ... Global Seaweed Fertilizer Industry” is a professional ... Fertilizer market. The report provides basic Seaweed ... application, and industry chain structure as well ... international market analysis, including domestic market as ...
    (Date:8/21/2014)... N.Y. (PRWEB) August 21, 2014 The ... the first private college in the Mid-Hudson Region to ... will now begin accepting applications from qualified “high-technology” businesses ... “We are very pleased to have been selected for ... Governor Cuomo’s transformative initiative to stimulate economic development in ...
    (Date:8/21/2014)... Cord Blood Corporation (NYSE: CO ) (the ... for the first quarter of fiscal year 2015 on ... US.  The Company will host a ... 29, 2014 to discuss its financial performance and give ... by a question and answer session.  Interested parties may ...
    (Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
    Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
    ... the second time this year, a tech-based company in Wisconsin ... the public. Called an initial public offering, this kind of ... investors who are directly involved, but to others who may ... biotechnology company, has filed papers with the Securities and ...
    ... as are demands for the CIO's attention: electronic health ... and the like, combined with the standard fare of ... , ,The C-suite also is going through a major ... is that ability to execute corporate strategy, rather than ...
    ... Wis. - With the goal of transforming more ... Wisconsin-Madison has approved a new research entity - ... institute is a collaboration of the four UW-Madison health ... Veterinary Medicine. It will partner with the Marshfield Clinic ...
    Cached Biology Technology:Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3Fire your CIO? If he's not implementing strategy, show him the door 2Fire your CIO? If he's not implementing strategy, show him the door 3
    (Date:8/22/2014)... August 21, 2014 Diabetes affects nearly 10 ... complaints of diabetics: constant finger pricking to test ... Chemical Biology reports the development of a protein ... accurate results for diabetes patients. In the American ... Daunert, Ph.D., shows off her "designer protein" that ...
    (Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
    (Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
    Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
    ... the challenges for forests and the costs of ... factors surrounding biofuel crop production and its implications ... Sustainability Reports. Produced by the Ecological Society of ... scientists, and sponsored by the Energy Foundation, these ...
    ... University] Scientists have long known that the brain,s ... how the brain processes more complex and unfamiliar knowledge. ... in the journal Neuron , a team of ... tested whether the frontal lobe has the ability to ...
    ... largest fresh-water floods in Earth,s history happened about 17,000 years ... now occupied in part by the city of Wasilla, widely ... was one of at least four "megafloods" as Glacial Lake ... more than 3,500 square miles in the Copper River Basin ...
    Cached Biology News:Sustainable biofuels from forests, grasslands and rangelands 2Sustainable biofuels from forests, grasslands and rangelands 3Complex brain functions help adapt to new situations and stimuli 2Research shows part of Alaska inundated by ancient megafloods 2Research shows part of Alaska inundated by ancient megafloods 3
    ... the proven features of the pET, BacVector ... all of the benefits and versatility of ... The pTriEx vectors have been extensively tested ... all three expression systems. In each case, ...
    ... the first instrument engineered to match the ... by thousands of research centers worldwide. It ... which are ideally suited for high-speed temperature ... extremely high surface-area-to-volume ratio. ,By combining glass ...
    ... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
    ... Clear amber to slightly cloudy ... 10 vials per set, each containing ... homogenized in the following proportions by ... A (mannide monooleate emulsifier), and 0.1% ...
    Biology Products: